AbCellera Biologics Inc. (ABCL) Research
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Market snapshot
- Symbol
- ABCL
- Price
- $5.53
- Day change
- +1.65%
- Market cap
- $1.7B
- P/E ratio
- -11.64x
- 52-week range
- 2.745-6.79
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $7.50
Recent news
- Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
- Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
Peer companies
Recent insider activity
- Hayden Michael R — A-Award (111701 shares) on 2026-06-11
- Quake Stephen — A-Award (111701 shares) on 2026-06-11
- Montalbano John S. — A-Award (111701 shares) on 2026-06-11
- Sandor Victor — trade (0 shares) on 2026-06-01
- Montalbano John S. — P-Purchase (20000 shares) on 2026-05-14
Open AbCellera Biologics Inc. (ABCL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.